subscribeSubscribe
Ipca Labs Generic Risperidone Receives Approval in US

Ipca Labs Generic Risperidone Receives Approval in US
FDA
26 Jun 2024
Share Share
Teva and MedinCell`s long-acting schizophrenia med wins in phase 3

Teva and MedinCell`s long-acting schizophrenia med wins in phase 3
FIERECE PHARMA
09 May 2024
Share Share
New Pharmacokinetic Modeling Data Presented by Teva at SIRS 2024

New Pharmacokinetic Modeling Data Presented by Teva at SIRS 2024
BUSINESSWIRE
06 Apr 2024
Share Share
Lyndra Announces Positive Data from Phase 3 Study with Oral Weekly Risperidone

Lyndra Announces Positive Data from Phase 3 Study with Oral Weekly Risperidone
BUSINESSWIRE
04 Jan 2024
Share Share
UZEDY Injectable Suspension Significantly Prolongs Time to Schizophrenia

UZEDY Injectable Suspension Significantly Prolongs Time to Schizophrenia
BUSINESSWIRE
01 Nov 2023
Share Share
Teva to Present Data for AUSTEDO Extended-Release Tablets, AUSTEDO Tablets

Teva to Present Data for AUSTEDO Extended-Release Tablets, AUSTEDO Tablets
BUSINESSWIRE
06 Sep 2023
Share Share
Teva to Present Data Demonstrating UZEDY Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse

Teva to Present Data Demonstrating UZEDY Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse
BUSINESSWIRE
20 May 2023
Share Share
FDA approves Teva, MedinCell`s long-acting schizophrenia therapy

FDA approves Teva, MedinCell`s long-acting schizophrenia therapy
Kevin Dunleavy FIERCE PHARMA
02 May 2023
Share Share
Teva and MedinCell Announce FDA Approval of UZEDY Injectable Suspension

Teva and MedinCell Announce FDA Approval of UZEDY Injectable Suspension
BUSINESSWIRE
28 Apr 2023
Share Share
US FDA approves Luye Pharma’s schizophrenia treatment Rykindo

US FDA approves Luye Pharma’s schizophrenia treatment Rykindo
PHARMACEUTICAL TECHNOLOGY
16 Jan 2023
Share Share